Early detection and prevention of diabetic nephropathy: A challenge calling for mandatory action for Mexico and the developing world

Kidney International, Supplement

Volumn 68, Issue 98, 2005, Pages

  Correa Rotter, Ricardo ^a   González Michaca, Luis ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

CME; Developing nations; Diabetic nephropathy; Mexico; Prevention; Primary physicians

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEVELOPING COUNTRY; DIABETIC NEPHROPATHY; DIAGNOSTIC TEST; DISEASE COURSE; EARLY DIAGNOSIS; ECONOMIC ASPECT; EPIDEMIOLOGICAL DATA; EXPERIENCE; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; KIDNEY FAILURE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEXICO; MICROALBUMINURIA; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REMISSION; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SOCIAL STATUS; SOCIAL SUPPORT; TREATMENT PLANNING; ALBUMINURIA; BLOOD GLUCOSE MONITORING; DEMOGRAPHY; HEALTH CARE COST; HEALTH PRACTITIONER; LIFESTYLE; REVIEW; SMOKING CESSATION; SOCIAL ASPECT; DIABETES MELLITUS; EDUCATION; GENERAL PRACTITIONER; INFANT; MEDICAL EDUCATION; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; INFANT; INFECTION; MALE; MEXICO; MIDDLE AGED; PHYSICIANS, FAMILY;

EID: 33644594763     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09813.x     Document Type: Article

References (44)

1. OMRAN AR: The epidemiologic transition: A key of the epidemiology of population change. Milibank Mem Fund Q 49:509-538, 1971
2. REDDY KS, YUSUF SL: Emerging epidemic of cardiovascular disease in developing countries. Circulation 97:596-601, 1998
3. WORLD BANK: World Development Report: Investing in Health, New York, Oxford University Press, 1993
4. RIVERA JA, BARQUERA S, CAMPIRANO F, TOVAR V, et al: Epidemiological and nutritional transition in Mexico: Rapid increase of non-communicable chronic diseases and obesity. Public Health Nutr 5:113-122, 2002
5. PARTIDA BUSH V: Proyecciones de la población económicamente activa, de la matrícula educativa de los hogares y las viviendas y de la población por tamaño de la localidad, México, Consejo Nacional de Población, 1999, pp 17-19, Available at: http://www.conapo. gob.mx/publicaciones/Proyecciones/pdf/proypea.pdf, Accessed 2003
6. MURRAY CJL, LOPEZ AD: Global Comparative Assessments in the Health Sector, Geneva, Switzerland, World Health Organization, 1994
7. PEARSON TA, JAMISON DT, TERGO-GAUDERIES J: Cardiovascular disease, in Disease Control Priorities in Developing Countries, edited by Jamison DT, Mosley WH, New York, Oxford University Press, 1993 pp 577-599
8. PETO R, LOPEZ AD, BOREHAM J, et al: Mortality from smoking worldwide. Br Med Bull 52:12-21, 1996
9. WORLD HEALTH ORGANIZATION: Tobacco or Health? First Global Status Report, Geneva, Switzerland, World Health Organization, 1996
10. POPKIN BM: The nutrition transition in low-income countries: An emerging crisis. Nutr Rev 52:285-298, 1994
11. LANG T: The public health impact of globalization of food trade, in Diet, Nutrition and Chronic Disease: Lessons from Contrasting Worlds, edited by Shetty PS, McPherson K, Chichester, United Kingdom, Wiley, 1997, pp 173-187
12. DREWNOWSKI A, POPKIN BM: The nutrition transition: New trends in the global diet. Nutr Rev 55:31-43, 1997
13. WHELTON PK, BRANCATI FL, APPEL LJ, KLAG MJ: The challenge of hypertension and atherosclerotic cardiovascular disease in economically developing countries. High Blood Press 4:36-45, 1995
14. ENCUESTA NACIONAL DE ENEERMEDADES CRÓNICAS 2000: Dirección General de Epidemiología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D.F. Secretaría de Salud, 2000
15. ENCUESTA NACIONAL DE ENEERMEDADES CRÓNICAS 1993: Dirección General de Epidemiología, Instituto Nacional de la Nutrición, México, D.F., Secretaría de Salud, 1993
16. GILL-RANDALL R, ADAMS D, LEWIS M, et al: Type 2 diabetes mellitus - Genes or intrauterine environment? An embryo transfer paradigm in rats. Diabetologia 47:1354-1359, 2004
17. BAIER LJ, HANSON RL: Genetic studies of the etiology of type 2 diabetes in Pima Indians: Hunting for pieces to a complicated puzzle. Diabetes 53:1181-1186, 2004
18. VELÁZQUEZ O, LARA-ESQUEDA A, PEÑA A: La Diabetes en México, in Boletín Epidemiológico en Español, Panamerican Health Organization. 8, 1999, pp 2
19. Reuters AlertNet: Diabetes now Mexico's leading cause of death. Report from the Mexican Minister of Health, available at: www.alertnet.org/thenews/ newsdesk/N24404782.htm, Reuters, accessed August 24, 2004
20. ZIMMET P: Globalization, coca-colonization and the chronic disease epidemic: Can the doomsday scenario be averted? J Intern Med 247:301-310, 2000
21. SONGER T: The economic costs of NIDDM. Diabetes Metabol Rev 8:389-404, 1992
22. PARVING H-H: Diabetic nephropathy: Prevention and treatment. Kidney Int 60:2041-2055, 2001
23. KING H, AUBERT RE, HERMAN WH: Global burden of diabetes 1995-2025, prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998
24. VIBERTI G: The need for tighter control of cardiovascular risk factors in diabetic patients. J Hypertens 21(Suppl 1):S3-6, 2003
25. LANE JT: Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus. A temporal perspective. Am J Physiol Renal 286:F442-50, 2004
26. RAVID M, BROSH D, RAVID-SAFRAN D, et al: Main risk factors for nephropathy in type 2 DM are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004, 1998
27. THE DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT): Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 35:530-545, 1986
28. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 47:1703-1720, 1995
29. PRAGA M: Slowing the progression of renal failure. Kidney Int 61(Suppl 80):18-22, 2002
30. WAUGH NR, ROBERTSON AM: Protein restriction for diabetic renal disease. Cochrane Database Syst Rev (2):CD002181, 2000
31. PIJLS LT, DE VRIES H, DONKER AJ, VAN EIJK JT: The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: A randomized trial. Nephrol Dial Transplant 14:1445-1453, 1999
32. FASSI A, SANGALLI F, COLOMBI F, et al: Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. Am J Kidney Dis 33:267-275, 1999
33. UNITED KINGDOM PROSPECTIVE DIABETES STUDY GROUP (UKPDS): Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
34. CORESH J, ASTOR B, SARNAK MJ: Evidence for increased cardiovascular risk in patients with chronic kidney disease. Curr Op Nephrol Hypertens 13:73-81, 2004
35. MACISAAC RJ, JERUMS G, COOPER ME: New insights into the significance of microalbuminuria. Curr Opin Nephrol Hypertens 13:83-91, 2004
36. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
37. YUYUN MF, KHAW KT, LUBEN R, et al: Microabuminuria independently predicts all-cause and cardiovascular mortality in British population: The European Prospectiva Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidem 33:189-198, 2004
38. BRENNER BM, DE ZEEUW D, PARVING HH, et al: RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
39. LEWIS EJ, BERL T, RAZ I, et al, FOR THE COLLABORATIVE STUDY GROUP: Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
40. HOSTETTER TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 345:910-912, 2001
41. HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICROHOPE substudy. Lancet 355:253-259, 2000
42. LAMEIRE N, WAUTERS JP, GORRIZ TERUEL JL, et al: An update on the referral pattern of patients with end-stage renal disease. Kidney Int 61:S27-S34, 2002
43. GÆDE P, VEDEL P, LARSEN N, et al: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
44. BROWN CA, BELFIELD CR, FIELD SJ: Cost effectiveness of continuing professional development in health care: A critical review of the evidence. BMJ 324:652-655, 2002